C Colombo1, R Miceli2, C Le Péchoux3, E Palassini4, C Honoré5, S Stacchiotti4, O Mir6, P G Casali4, J Dômont6, M Fiore1, A Le Cesne6, A Gronchi7, S Bonvalot5. 1. Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 2. Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 3. Department of Radiotherapy, Institute Gustave Roussy, Villejuif, France. 4. Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. 5. Department of Surgery, Institute Gustave Roussy, Villejuif, France. 6. Department of Cancer Medicine, Institute Gustave Roussy, Villejuif, France. 7. Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: alessandro.gronchi@istitutotumori.mi.it.
Abstract
BACKGROUND: To analyse the natural history of extra-abdominal wall desmoid-type fibromatosis (DF) and compare outcome in patients who underwent initial surgery with those who did not. PATIENTS AND METHODS: All consecutive patients affected by primary sporadic extra-abdominal wall DF observed between January 1992 and December 2012 were included. Patients were divided into surgical (SG) or non-surgical groups (NSG) according to initial treatment. Relapse free survival was calculated for SG, and crude cumulative incidence (CCI) of switching to surgery or other treatments for NSG. RESULTS: 216 patients were identified, 94 in SG (43%), 122 in NSG (57%). A shift towards a more systematic use of a conservative approach (78% of all comers) was observed in the latter years (2006-2012), although a small proportion of patients (28%) had been offered the conservative strategy even in the early period (1992-2005). Median follow-up (FU) was 49 mo. (interquartile (IQ), 20-89 mo.), 76 months for SG and 39 months for NSG. 5-year relapse-free survival (RFS) for SG was 80% (95% confidence interval (CI), 72-89%). For the NSG, 5-year CCI of switching to surgery was 5% (95% CI: 1.7%, 14%), and 51% to other treatments (95% CI: 41%, 65%). 27 (20%) NSG patients underwent spontaneous regression. CONCLUSION: A non-surgical approach to extra-abdominal wall DF allowed surgery to be avoided in the majority of patients. This approach can be safely proposed and surgery offered as an option in selected cases.
BACKGROUND: To analyse the natural history of extra-abdominal wall desmoid-type fibromatosis (DF) and compare outcome in patients who underwent initial surgery with those who did not. PATIENTS AND METHODS: All consecutive patients affected by primary sporadic extra-abdominal wall DF observed between January 1992 and December 2012 were included. Patients were divided into surgical (SG) or non-surgical groups (NSG) according to initial treatment. Relapse free survival was calculated for SG, and crude cumulative incidence (CCI) of switching to surgery or other treatments for NSG. RESULTS: 216 patients were identified, 94 in SG (43%), 122 in NSG (57%). A shift towards a more systematic use of a conservative approach (78% of all comers) was observed in the latter years (2006-2012), although a small proportion of patients (28%) had been offered the conservative strategy even in the early period (1992-2005). Median follow-up (FU) was 49 mo. (interquartile (IQ), 20-89 mo.), 76 months for SG and 39 months for NSG. 5-year relapse-free survival (RFS) for SG was 80% (95% confidence interval (CI), 72-89%). For the NSG, 5-year CCI of switching to surgery was 5% (95% CI: 1.7%, 14%), and 51% to other treatments (95% CI: 41%, 65%). 27 (20%) NSG patients underwent spontaneous regression. CONCLUSION: A non-surgical approach to extra-abdominal wall DF allowed surgery to be avoided in the majority of patients. This approach can be safely proposed and surgery offered as an option in selected cases.
Authors: Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz Journal: N Engl J Med Date: 2018-12-20 Impact factor: 91.245
Authors: Kirsi Santti; Annette Beule; Laura Tuomikoski; Mikko Rönty; Anna-Stina Jääskeläinen; Kauko Saarilahti; Hanna Ihalainen; Maija Tarkkanen; Carl Blomqvist Journal: Strahlenther Onkol Date: 2017-01-02 Impact factor: 3.621
Authors: Danique L M van Broekhoven; Dirk J Grünhagenl; Thijs van Dalen; Frits van Coevorden; Han J Bonenkamp; Lukas B Been; Marc H A Bemelmans; Sander D S Dijkstra; Chiara Colombo; Alessandro Gronchi; Cornelis Verhoef Journal: BMC Cancer Date: 2016-08-26 Impact factor: 4.430